495 related articles for article (PubMed ID: 8537970)
1. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Restifo NP; Marincola FM; Kawakami Y; Taubenberger J; Yannelli JR; Rosenberg SA
J Natl Cancer Inst; 1996 Jan; 88(2):100-8. PubMed ID: 8537970
[TBL] [Abstract][Full Text] [Related]
2. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
Chang CC; Campoli M; Restifo NP; Wang X; Ferrone S
J Immunol; 2005 Feb; 174(3):1462-71. PubMed ID: 15661905
[TBL] [Abstract][Full Text] [Related]
3. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
4. Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.
Jakobsen MK; Restifo NP; Cohen PA; Marincola FM; Cheshire LB; Linehan WM; Rosenberg SA; Alexander RB
J Immunother Emphasis Tumor Immunol; 1995 May; 17(4):222-8. PubMed ID: 7582258
[TBL] [Abstract][Full Text] [Related]
5. The CD8+ T cell repertoire in beta 2-microglobulin-deficient mice is biased towards reactivity against self-major histocompatibility class I.
Glas R; Ohlén C; Höglund P; Kärre K
J Exp Med; 1994 Feb; 179(2):661-72. PubMed ID: 8294874
[TBL] [Abstract][Full Text] [Related]
6. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.
Garcia-Lora A; Martinez M; Algarra I; Gaforio JJ; Garrido F
Int J Cancer; 2003 Sep; 106(4):521-527. PubMed ID: 12845647
[TBL] [Abstract][Full Text] [Related]
7. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells.
Chang CC; Ogino T; Mullins DW; Oliver JL; Yamshchikov GV; Bandoh N; Slingluff CL; Ferrone S
J Biol Chem; 2006 Jul; 281(27):18763-73. PubMed ID: 16648140
[TBL] [Abstract][Full Text] [Related]
8. Overproduction and secretion of beta 2-microglobulin by a rat thymic epithelial cell line that expresses MHC class I heavy chain.
Dargemont C; Dunon D; Salamero J; Deugnier MA; Davoust J; Thiery JP
J Cell Sci; 1991 Apr; 98 ( Pt 4)():559-65. PubMed ID: 1860902
[TBL] [Abstract][Full Text] [Related]
9. The role of beta-2 microglobulin in temperature-sensitive and interferon-gamma-induced exocytosis of HLA class I molecules.
Tatake RJ; Ferrone S; Zeff RA
Transplantation; 1992 Sep; 54(3):395-403. PubMed ID: 1412716
[TBL] [Abstract][Full Text] [Related]
10. Functional cell surface expression by a recombinant single-chain class I major histocompatibility complex molecule with a cis-active beta 2-microglobulin domain.
Lee L; McHugh L; Ribaudo RK; Kozlowski S; Margulies DH; Mage MG
Eur J Immunol; 1994 Nov; 24(11):2633-9. PubMed ID: 7957555
[TBL] [Abstract][Full Text] [Related]
11. Highly lytic CD8+, alpha beta T-cell receptor cytotoxic T cells with major histocompatibility complex (MHC) class I antigen-directed cytotoxicity in beta 2-microglobulin, MHC class I-deficient mice.
Apasov S; Sitkovsky M
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2837-41. PubMed ID: 8464897
[TBL] [Abstract][Full Text] [Related]
12. Selective loss of beta 2-microglobulin mRNA in human colon carcinoma.
Momburg F; Koch S
J Exp Med; 1989 Jan; 169(1):309-14. PubMed ID: 2642530
[TBL] [Abstract][Full Text] [Related]
13. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma.
Gastl G; Ebert T; Finstad CL; Sheinfeld J; Gomahr A; Aulitzky W; Bander NH
J Urol; 1996 Jan; 155(1):361-7. PubMed ID: 7490887
[TBL] [Abstract][Full Text] [Related]
14. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.
Hicklin DJ; Wang Z; Arienti F; Rivoltini L; Parmiani G; Ferrone S
J Clin Invest; 1998 Jun; 101(12):2720-9. PubMed ID: 9637706
[TBL] [Abstract][Full Text] [Related]
15. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells.
Jhaver KG; Rao TD; Frey AB; Vukmanović S
J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863
[TBL] [Abstract][Full Text] [Related]
16. Control of thymus-independent intestinal intraepithelial lymphocytes by beta 2-microglobulin.
Neuhaus O; Emoto M; Blum C; Yamamoto S; Kaufmann SH
Eur J Immunol; 1995 Aug; 25(8):2332-9. PubMed ID: 7664795
[TBL] [Abstract][Full Text] [Related]
17. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
Propper DJ; Chao D; Braybrooke JP; Bahl P; Thavasu P; Balkwill F; Turley H; Dobbs N; Gatter K; Talbot DC; Harris AL; Ganesan TS
Clin Cancer Res; 2003 Jan; 9(1):84-92. PubMed ID: 12538455
[TBL] [Abstract][Full Text] [Related]
18. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.
del Campo AB; Kyte JA; Carretero J; Zinchencko S; Méndez R; González-Aseguinolaza G; Ruiz-Cabello F; Aamdal S; Gaudernack G; Garrido F; Aptsiauri N
Int J Cancer; 2014 Jan; 134(1):102-13. PubMed ID: 23784959
[TBL] [Abstract][Full Text] [Related]
19. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of defective antigen processing in human prostate cancer.
Sanda MG; Restifo NP; Walsh JC; Kawakami Y; Nelson WG; Pardoll DM; Simons JW
J Natl Cancer Inst; 1995 Feb; 87(4):280-5. PubMed ID: 7707419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
